טוען...
Adjuvant Endocrine Therapy in Early Postmenopausal Breast Cancer
Five years of adjuvant tamoxifen treatment has been the gold standard for women with early hormone-responsive breast cancer. Results from two large phase III, adjuvant studies have indicated that the third-generation aro-matase inhibitors (AIs) letrozole and anastrozole offer greater protection agai...
שמור ב:
| Main Authors: | , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
S. Karger GmbH
2008
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2931103/ https://ncbi.nlm.nih.gov/pubmed/20824026 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000155548 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|